Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2026)
Arcus Biosciences' Current Deferred Revenue came in at $19 million for Q2 2026, down 73.2% from $71 million a year earlier and down 44.1% from the prior quarter.
Powered by 
Analysis
Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2026) Analysis & Trends
At the end of FY2025, Arcus Biosciences' Current Deferred Revenue was $35 million, down 58.8% from FY2024.
- Current Deferred Revenue has declined in each of the last four years, with a five-year compound annual growth rate of -14.0% (FY2020 to FY2025).
- Going back by year, Current Deferred Revenue was $85 million in FY2024 (-6.6%), $91 million in FY2023 (-6.2%), $97 million in FY2022 (-4.9%) and $102 million in FY2021 (+36.8%).
- The Q2 2026 figure represents the lowest quarterly Current Deferred Revenue since Q2 2020.
- Year-over-year, Current Deferred Revenue has declined for seven consecutive quarters, with an average decline of 39.9% over the last eight quarters.
- The fastest year-over-year change in Current Deferred Revenue over five years came in Q3 2022 (growth of 38.9%), and the weakest in Q2 2026 (a decline of 73.2%).
- Business Quant data shows RCUS's Current Deferred Revenue at $34 million (Q1 2026), $35 million (Q4 2025) and $52 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn |
| 10 | Arcus Biosciences | 3.26 Bn | -77.18 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.00 Mn |
| Mar 31, 2026 | 34.00 Mn |
| Dec 31, 2025 | 35.00 Mn |
| Sep 30, 2025 | 52.00 Mn |
| Jun 30, 2025 | 71.00 Mn |
| Mar 31, 2025 | 72.00 Mn |
| Dec 31, 2024 | 85.00 Mn |
| Sep 30, 2024 | 105.00 Mn |
| Jun 30, 2024 | 113.00 Mn |
| Mar 31, 2024 | 124.00 Mn |
| Dec 31, 2023 | 91.00 Mn |
| Sep 30, 2023 | 103.00 Mn |
| Jun 30, 2023 | 103.00 Mn |
| Mar 31, 2023 | 97.00 Mn |
| Dec 31, 2022 | 97.00 Mn |
| Sep 30, 2022 | 103.29 Mn |
| Jun 30, 2022 | 90.12 Mn |
| Mar 31, 2022 | 89.31 Mn |
| Dec 31, 2021 | 102.00 Mn |
| Sep 30, 2021 | 74.34 Mn |
API Access
Arcus Biosciences Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RCUS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "current-deferred-revenue", "ticker": "RCUS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=RCUS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();